LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles.
Sign Up to like articles & get recommendations!
A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study.
11506Background: U-LMS and ST-LMS are rare tumors with poor prognosis when locally advanced or metastatic, and with moderate chemosensitivity. Overall response rates (ORR) given in the 1st-line set... Click to show full abstract
11506Background: U-LMS and ST-LMS are rare tumors with poor prognosis when locally advanced or metastatic, and with moderate chemosensitivity. Overall response rates (ORR) given in the 1st-line set...
Share on Social Media:
  
        
        
        
Sign Up to like & get recommendations! 0
Related content
More Information
            
News
            
Social Media
            
Video
            
Recommended
               
Click one of the above tabs to view related content.